SHAWNEE, Kan., Jan. 22, 2014 /PRNewswire/ -- Bayer HealthCare LLC Animal Health division today introduced the Remend® line, the newest addition to Bayer's DVM® family of products, at the North American Veterinary Conference (NAVC) in Orlando. This topical line includes: Remend® Wound Spray Gel, Remend® Corneal Repair Gel and Remend® Eye Lubricating Drops. All formulations feature specialized options to help veterinarians manage wounds, abrasions and lacerations, and provide lubrication for dry eyes in dogs and cats.
"Bayer's introduction of the Remend® product line reinforces our commitment to animal health and well-being by providing veterinarians with easy-to-use, pet wound care products that pet owners can use on their dogs and cats," said Ian Spinks, president and general manager, Bayer HealthCare LLC Animal Health division, North America. "It also reflects Bayer's mission Science for a Better Life and our ongoing effort to provide veterinary practices with modern and innovative products."
The Remend® wound care products, intended to aid in the management of skin wounds and superficial corneal ulcers, contain advanced, cross-linked, hyaluronic acid (HA), which provides a "scaffolding matrix" to promote cell migration at the wound site and, in turn, aids dogs' and cats' own bodily healing processes.
"Bayer's exclusive advanced cross-linked HA technology has many beneficial properties for wound healing," said Cristiano von Simson, DVM, MBA, Director, Veterinary Technical Services, Bayer HealthCare LLC Animal Health division. "The unique technology in Remend® helps foster an environment conducive to re-epithelialization at the site of the wound, which may be beneficial in a variety of injuries to the skin and eyes."
Remend® family of healing care
The three specialized options launching exclusively in the veterinary channel include:
- Remend® Wound Spray Gel, a convenient and cost effective product that helps support the healing of superficial skin wounds including cuts, abrasions and lacerations on dogs and cats.
- Remend® Corneal Repair Gel, designed for superficial corneal ulcers and abrasions, that can be used as part of an overall treatment plan in patients where twice daily administration of cross-linked hyaluronic acid technology is appropriate.*
- Remend® Eye Lubricating Drops that provides hydration and lubrication for dry or irritated eyes. A recent study in dogs demonstrated that Remend® Eye Lubricating Drops may lead to improvement in some of the characteristic clinical signs of dry eyes. In some patients, twice daily administration may be appropriate.1 Having fewer doses may enhance owner compliance.
About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, agriculture and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 18.6 billion (2012), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover, develop, manufacture and market products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 54,900 employees (Dec. 31, 2012) and is represented in more than 100 countries. More information at www.healthcare.bayer.com.
* Does not contain an antibiotic
1 Williams, DL, Mann, BK. (2013) A Crosslinked HA-Based Hydrogel Ameliorates Dry Eye Symptoms in Dogs. International Journal of Biomaterials, Vol. 2013, Article ID 460437, 8 pages, doi: 10.1155/2013/460437.
Staci Gouveia, Tel. 203.809.9008
Lauren Dorsch, Tel. 913.827.6306
Find more information about Bayer HealthCare Animal Health at www.animalhealth.bayerhealthcare.com
Follow us on Twitter: @Bayer4animalsUS
Follow us on Facebook: http://www.facebook.com/healthcare.bayer
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.
SOURCE Bayer HealthCare Animal Health